Amylyx Advances Avexitide Trial for Post-Bariatric Hypoglycemia with Q3 2026 Data Expected — Amylyx Pharmaceuticals, Inc.

Event summary

Amylyx completed enrollment in its Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH), with topline data expected in Q3 2026.
The company selected AMX0318 as a development candidate for PBH and other rare diseases, following preclinical success.
Amylyx reported a net loss of $144.7 million for 2025, down from $301.7 million in 2024, with cash runway extending into 2028.
Early safety data from the Phase 1 LUMINA trial of AMX0114 for ALS showed no treatment-related serious adverse events.

The big picture

Amylyx is positioning itself as a leader in rare disease therapeutics, with avexitide poised to become the first FDA-approved treatment for PBH. The company's strategic focus on high-unmet-need conditions aligns with broader industry trends toward precision medicine and targeted therapies. Success in these areas could validate its pipeline strategy and attract further investment.

What we're watching

Regulatory Pathway: Whether avexitide can secure FDA approval by 2027, given the Breakthrough Therapy Designation and positive Phase 2 data.
Pipeline Progress: The pace at which AMX0318 advances through IND-enabling studies toward a potential 2027 filing.
Financial Sustainability: How Amylyx manages its cash runway into 2028 amid ongoing clinical and commercialization efforts.